David E. Potter

David E. Potter

Professor and Chair of Pharmaceutical Sciences

Texas A&M Rangel College of Pharmacy
1010 W. Ave. B
Kingsville, Texas   78363

Phone: 361-221-0731
Fax: 361-221-0793
dpotter@pharmacy.tamhsc.edu

Education and Training

University of Kansas Medical Center, Kansas City, Kansas
Ph.D. in Pharmacology, 1969

Texas Tech University, Lubbock, Texas
Bachelor of Arts, Zoology, 1960

Teaching Interests

  • Neuroendocrinology
  • Ocular Pharmacology

Research Interests

  • Neuroendocrinology
  • Ocular Pharmacology

Selected Publications

  • Burke JA, Potter DE.  Ocular effects of a relatively selective alpha2 agonist (UK-14, 304-18) in cats, rabbits and monkeys.  Curr Eye Res 5:665-676, 1986. (UK-14, 304-18 currently marketed as brimonidine [Alphagan ®] for glaucoma)
  • Zhou L, Thompson WJ, Potter DE. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 40:1745-1752, 1999.
  • Zhou L, Thompson WJ, Potter DE. Functional identification of phosphodiesterase activity in human trabecular meshwork cells. J Ocular Pharmacol Ther 16:317-322, 2000.
  •  Dortch-Carnes J, Potter DE.  Inhibition of cAMP accumulation by kappa-receptor activation in    isolated iris-ciliary bodies: Roles of phosphodiesterase and protein kinase C.  J Pharmacol Exp Ther 301:599-604, 2002.
  •  Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, Paulsen DF.  Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats.  Cells Tissues Organs 171:188-198, 2002.
  •   Chu TC, He Q, Potter DE.  Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent.  J Ocular Pharmacol Ther 18:507-  514, 2002.
  •  Chu TC, Potter DE.  Ocular hypotension induced by electroacupuncture.  J Ocular Pharm Ther 18:293-305, 2002.
  •  Ogidigben MJ, Chu TC, Potter DE.  Naphazoline-induced neuroendocrine changes: Increases in ANP and cGMP levels, but suppression of NE, 3H-NE, cAMP levels in rabbit eyes. Pharmacology 65:155-161, 2002.
  •  Dortch-Carnes J, Potter DE.  Effect of bremazocine, a kappa-opioid receptor agonist, on inositol phosphate formation in isolated iris-ciliary bodies.  Pharmacology 66: 100-106, 2002.
  •   Russell KRM, Potter DE.  Dynorphin modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of kappa-opioid receptors.  Exp Eye Res 75: 259-270,     2002. 
  • Ogidigben MJ,Potter DE  Pharmacological evidence of a role for prejunctional imidazoline (I-1) receptors in ocular function.  Curr. Eye Res. 25: 267-270, 2002.
  • von Deutsch DA, Abukhalaf IK, Wineski LE, Silvestrov NA, Bayorh MA, Potter DE.  Changes in muscle proteins and spermidine content in response to unloading and clenbuterol   treatment. Can. J. Physiol. Pharmacol. 81:28-39, 2003.
  •  Dortch-Carnes J, Potter DE.  Delta-opioid agonist-stimulated inositol phosphate formation in isolated  rabbit iris-ciliary bodies: role of Gi/o proteins and Gbg  subunits.  Exp Eye Res     77: 647:652, 2003.
  •  Potter DE, Russell KR, Manhiani M.  Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility.  J Pharmacol Exp Ther 309: 548-553,    2004.
  •  Dortch-Carnes J, Potter DE. Bremazocine: a kappa-opioid receptor agonist with potent   analgesic and other pharmacologic properties.  CNS Drug Rev 11: 195-212, 2005.
  •  Husain, S, Potter, D.E.  The opioidergic system: potential roles and therapeutic indications in the eye. J. Ocul. Pharmacol. Ther. 24: 117-140, 2008.
  •  Husain, S, Potter, DE, Crosson, CE. Opioid receptor activation protects the retina from ischemic injury. Invest. Ophthalmol. Vis. Sci., 50: 3853-3859, 2009.
  •  Husain, S., Abdul, Y.,Potter, D.E. Non-analgesic effects of opioids: neuroprotection in the retina. Curr. Pharm. Des. 18: 6101-6108, 2012.

National Service and Recognition

  • Elected Gold Fellow (FARVO [Association for Research in Vision and Ophthalmology])
  • Associate Editor, Journal Of Ocular Pharmacology & Therapeutics
  • Association for Ocular Pharmacology & Therapeutics, Secretary/Treasurer
  • Association for Ocular Pharmacology & Therapeutics, Vice President
  • National Eye Institute, Study Section Member and Panel Member for five-year strategic plan (Glaucoma)